Proteostasis Network in Neurodegeneration

Migration, Crosslink

📖

Proteostasis Network in Neurodegeneration

active

wiki page Created: 2026-04-02T07:19:57 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-mechanisms-proteostasis-network

📖 Wiki Page

mechanism2529 wordssynced 2026-04-02

Proteostasis Network in Neurodegeneration

Overview

The proteostasis network is a complex, interconnected system of cellular machinery responsible for maintaining protein homeostasis—ensuring proper protein folding, trafficking, degradation, and quality control. In neurodegenerative diseases, this network becomes overwhelmed or dysfunctional, leading to accumulation of misfolded proteins, proteotoxic stress, and ultimately neuronal death. [@balch2008]

The proteostasis network comprises three major interconnected systems: molecular chaperones, the [ubiquitin-proteasome system](/cell-types/ubiquitin-proteasome-system) (UPS), and the [autophagy](/entities/autophagy)-lysosome pathway (ALP). These systems work in concert to recognize, refold, or eliminate misfolded proteins before they can aggregate and cause cellular damage. [@klaips2014]

The Aging Proteostasis Decline

One of the most significant risk factors for neurodegenerative disease is aging itself. The proteostasis network undergoes age-related decline across multiple dimensions: [@kaushik2018]

Chaperone capacity decreases: Hsp70 and Hsp90 expression and activity decline with age
Proteasome activity reduces: Both 20S and 26S proteasome show age-related decreases
Autophagy flux diminishes: Lysosomal function and autophagosome formation decline
Unfolded protein response becomes dysregulated: Signaling becomes blunted and pro-apoptotic

...

Proteostasis Network in Neurodegeneration

Overview

The proteostasis network is a complex, interconnected system of cellular machinery responsible for maintaining protein homeostasis—ensuring proper protein folding, trafficking, degradation, and quality control. In neurodegenerative diseases, this network becomes overwhelmed or dysfunctional, leading to accumulation of misfolded proteins, proteotoxic stress, and ultimately neuronal death. [@balch2008]

The proteostasis network comprises three major interconnected systems: molecular chaperones, the [ubiquitin-proteasome system](/cell-types/ubiquitin-proteasome-system) (UPS), and the [autophagy](/entities/autophagy)-lysosome pathway (ALP). These systems work in concert to recognize, refold, or eliminate misfolded proteins before they can aggregate and cause cellular damage. [@klaips2014]

The Aging Proteostasis Decline

One of the most significant risk factors for neurodegenerative disease is aging itself. The proteostasis network undergoes age-related decline across multiple dimensions: [@kaushik2018]

Chaperone capacity decreases: Hsp70 and Hsp90 expression and activity decline with age
Proteasome activity reduces: Both 20S and 26S proteasome show age-related decreases
Autophagy flux diminishes: Lysosomal function and autophagosome formation decline
Unfolded protein response becomes dysregulated: Signaling becomes blunted and pro-apoptotic

This age-related decline creates a "proteostatic reserve" that is progressively depleted, making neurons increasingly vulnerable to protein aggregation. The exact mechanisms driving this decline include oxidative damage to protein quality control machinery, epigenetic changes affecting chaperone gene expression, and accumulation of damaged proteins that overwhelm the system. [@taylor2011]

Key Components

Molecular Chaperones

Molecular chaperones are proteins that assist in proper protein folding and prevent aggregation. They can be categorized into several families: [@lashley2008]

| Chaperone Family | Key Members | Function in Neurodegeneration |
|-----------------|-------------|------------------------------|
| Hsp70 | HSPA1A, HSPA8, HSPA5 (BiP) | Binds nascent and stress-damaged proteins; Hsp70 levels decline with age |
| Hsp90 | HSP90AA1, HSP90AB1 | Stabilizes mutant proteins; inhibition shows therapeutic promise |
| Small Hsp | HspB1 (Hsp27), HspB5 (αB-crystallin) | Prevents protein aggregation; protective in ALS and PD |
| Chaperonins | CCT complex, GroEL/GroES | Folds cytosolic proteins; mutations cause neurodegeneration |

Hsp70 System in Detail

The Hsp70 family represents the most versatile and evolutionarily conserved chaperone system. In neurons, Hsp70 performs multiple critical functions: [@mayer2005]

Co-translational folding: Assists ribosome-associated nascent chains

Protein refolding: Rescues misfolded proteins under stress conditions

Aggregate disassembly: Works with Hsp40 co-chaperones to resolve aggregates

Protein trafficking: Facilitates translocation across membranes

Quality control: Targets irreversibly damaged proteins for degradation

The Hsp70 system consists of multiple ATP-dependent cycles that require co-chaperones of the Hsp40 (DNAJ) family and nucleotide exchange factors (NEFs) such as BAG family proteins. In neurodegenerative diseases, Hsp70 function is compromised both by age-related decline and by direct sequestration into protein aggregates. [@hartl2011]

Hsp90 and Proteostasis

Hsp90 represents approximately 2-3% of total cellular protein and is essential for maintaining the conformation of numerous signaling proteins. In neurodegeneration, Hsp90 has a dual role: [@taipale2014]

Stabilizing mutant proteins: Many disease-causing mutations result in proteins that require Hsp90 for stability
Aggregation prevention: Hsp90 buffers against proteotoxic stress

Hsp90 inhibitors such as geldanamycin derivatives have shown promise in promoting mutant protein degradation, though toxicity remains a challenge. [@whitesell2014]

Ubiquitin-Proteasome System (UPS)

The [UPS](/mechanisms/ubiquitin-proteasome-system) is the primary pathway for targeted protein degradation. It involves: [@ciechanover2015]

Ubiquitination: E1, E2, and E3 enzymes conjugate ubiquitin to target proteins

Recognition: Ubiquitinated proteins are recognized by the 19S regulatory particle

Degradation: Proteins are unfolded and fed into the 20S core for proteolysis

Key E3 ligases in neurodegeneration: [@yao2020]

Parkin (PRKN): Mutations cause early-onset PD; responsible for mitophagy
CHIP (STUB1): Links Hsp70 to UPS; mutations cause HSP and SCA
TRIM proteins: Various TRIM proteins implicated in ALS and PD

Ubiquitin Chain Diversity

The complexity of ubiquitination extends beyond simple protein degradation. Different ubiquitin chain linkages convey distinct cellular signals: [@komander2012]

K48-linked chains: Traditional degradation signal
K63-linked chains: Non-degradative roles including signaling and autophagy
K27-linked chains: Aggresome targeting
M1-linked (linear) chains: NF-κB signaling
K29-linked chains: Lysosomal degradation

The deubiquitinating enzymes (DUBs) that reverse these modifications are themselves dysregulated in neurodegenerative disease, creating additional therapeutic targets. [@frake2015]

Autophagy-Lysosome Pathway

Autophagy degrades large protein aggregates and entire organelles. Three main types are relevant: [@mizushima2008]

Macroautophagy: Formation of autophagosomes that fuse with lysosomes
Chaperone-mediated autophagy (CMA): Direct translocation of specific proteins via LAMP-2A
Microautophagy: Direct engulfment by lysosomal membrane

Key autophagy proteins in neurodegeneration: [@nixon2011]

[mTOR](/mechanisms/mtor-signaling-pathway): Inhibition activates autophagy; mTOR inhibitors being tested in AD
Beclin-1 (BECN1): Reduced in AD brains; essential for autophagosome formation
p62/SQSTM1: Links ubiquitinated proteins to autophagy; mutations cause ALS/FTD
[TFEB](/entities/tfeb): Master regulator of lysosomal biogenesis; activation is protective

Chaperone-Mediated Autophagy Specificity

CMA represents a unique autophagy pathway that does not require vesicle formation. Instead, specific substrate proteins containing a KFERQ-like motif are recognized by Hsc70 (HSPA8) and transported directly across the lysosomal membrane via LAMP-2A. [@kiffin2007]

In neurodegenerative diseases:

[α-Synuclein](/proteins/alpha-synuclein) is a CMA substrate; mutations affecting CMA recognition contribute to accumulation
[TARDBP](/proteins/tardbp-protein) (TDP-43) is degraded via CMA; disruptions lead to aggregation
LAMP-2A expression declines with age, reducing CMA capacity

Mechanisms of Proteostasis Failure in Neurodegeneration

Alzheimer's Disease

In AD, proteostasis failure manifests at multiple levels: [@salomone2015]

[Aβ](/proteins/amyloid-beta) aggregation: Failure to clear monomeric Aβ leads to plaque formation
Tau pathology: Hyperphosphorylated tau escapes UPS degradation
ER stress: Accumulation of misfolded proteins triggers [UPR](/entities/unfolded-protein-response)
Lysosomal dysfunction: Cathepsin activity reduced in AD brains

The bidirectional relationship between Aβ and proteostasis is particularly important - not only does Aβ accumulation result from proteostasis failure, but Aβ oligomers can directly impair proteasome activity and autophagy flux, creating a feed-forward loop of proteostatic collapse. [@algarrahi2015]

Parkinson's Disease

PD shows selective vulnerability of dopaminergic [neurons](/entities/neurons): [@ouzounov2019]

[α-Synuclein](/proteins/alpha-synuclein): Normally degraded by both UPS and CMA; mutations cause accumulation
PINK1/Parkin: Mitochondrial quality control impaired in PD
GBA1: Lysosomal glucocerebrosidase deficiency increases α-synuclein burden
LRRK2: Mutations cause impaired autophagy and lysosomal function

The concept of "prion-like" spreading of α-synuclein pathology has important implications for proteostasis - extracellular aggregation seeds can be taken up by neighboring neurons and overwhelm their proteostatic capacity. [@prusiner2017]

ALS/FTD

Proteostasis collapse is central to motor neuron degeneration: [@chen2019]

[TDP-43](/mechanisms/tdp-43-proteinopathy): Aggregates in 95% of ALS cases; cleared by UPS and autophagy
[C9orf72](/entities/c9orf72): Hexanucleotide expansions cause toxic dipeptide repeat proteins
SOD1: Mutant SOD1 forms aggregates resistant to degradation
FUS: Nuclear import/export defects lead to cytoplasmic aggregation
TARDBP (TDP-43): Ubiquitinated inclusions in most ALS/FTD cases
GRN (Progranulin): Lysosomal dysfunction leading to TDP-43 pathology

The distinction between "loss-of-function" and "gain-of-toxic-function" in ALS/FTD protein aggregates remains an area of active investigation, with proteostasis failure contributing to both mechanisms. [@ling2013]

Huntington's Disease

HTT mutation creates proteostatic burden: [@orr2002]

Polyglutamine expansion: Causes protein misfolding and aggregation
Impaired autophagy: mTOR hyperactivation reduces autophagic flux
UPS dysfunction: [Huntingtin](/proteins/huntingtin) aggregates saturate degradation pathways

Frontotemporal Dementia (FTD)

FTD involves proteostasis impairment distinct from other neurodegenerative diseases: [@rascovsky2011]

Tau pathology: [MAPT](/proteins/tau) mutations cause Pick's disease and FTD spectrum
TDP-43 pathology: Most common pathology in sporadic FTD
FUS inclusions: Found in a subset of FTD cases
Progranulin deficiency: Leads to lysosomal dysfunction and microglial activation

Proteostasis Network Diagram

Mermaid diagram (expand to render)

Proteostasis and Mitochondrial Quality Control

The proteostasis network is intimately connected with mitochondrial quality control mechanisms. Mitochondria are particularly vulnerable to proteotoxic stress due to their high metabolic activity and ROS production. [@pickrell2015]

Mitophagy Pathways

PINK1/Parkin pathway: Activated by mitochondrial damage
BNIP3/NIX: Hypoxia-induced mitophagy receptor
FUNDC1: Outer membrane mitophagy receptor

Mitochondrial damage in neurodegenerative diseases overwhelms these quality control pathways, leading to accumulation of dysfunctional mitochondria that further impair cellular energetics and increase ROS production. [@liu2021]

Proteostasis at the Synapse

Synaptic proteins face unique proteostatic challenges: [@hegde2018]

High turnover requirements: Synaptic plasticity requires rapid protein synthesis and degradation
Local translation: Synaptic proteostasis must operate locally at synapses
Activity-dependent modifications: Synaptic activity modulates degradation rates

Dysregulation of synaptic proteostasis contributes to:

Impaired synaptic plasticity in AD
Synuclein pathology at neuromuscular junctions in PD
Synaptic dysfunction in ALS/FTD

Therapeutic Strategies

Chaperone-Based Therapies

Hsp90 inhibitors (geldanamycin derivatives): Promote degradation of mutant proteins
Hsp70 inducers (geranylgeranylacetone): Enhance cellular protective response
Small molecule chaperones (trehalose): Stabilize protein structure

UPS Modulation

Proteasome activators: Enhance degradation capacity
E3 ligase modulators: Specific targeting of disease proteins
Deubiquitinase inhibitors: Fine-tune ubiquitination dynamics

Autophagy Enhancement

mTOR inhibitors (rapamycin, everolimus): Activate macroautophagy
mTOR-independent activators (trehalose, carbamazepine): Enhance CMA
TFEB overexpression: Increase lysosomal biogenesis

Gene Therapy Approaches

AAV-delivered chaperones: Direct Hsp70/Hsp90 expression to neurons
Lysosomal enzyme replacement: GBA1 gene therapy for PD
Progranulin augmentation: Therapeutic strategies for GRN-related FTD

Emerging Therapeutic Approaches (2024-2026)

Autophagy-targeting chimeras (AUTACs): Novel molecules promoting selective autophagy [@takahashi2019]
Molecular glues: Small molecules promoting protein degradation via E3 ligases
Gene therapy for chaperone modulation: AAV-delivered Hsp70 and Hsp90 constructs
Integrated stress response modulators: Targeting the ISR to restore proteostasis

Biomarkers of Proteostasis Dysfunction

Several biomarkers can indicate proteostasis failure in neurodegenerative disease: [@karch2019]

| Biomarker | Source | Indicates |
|-----------|--------|-----------|
| Ubiquitinated proteins | CSF | UPS dysfunction |
| Proteasome activity | PBMCs, CSF | Proteasome capacity |
| p62/SQSTM1 | Blood, tissue | Autophagy inhibition |
| LAMP-2A | Blood, tissue | CMA decline |
| Hsp70 levels | CSF, blood | Chaperone response |
| LC3-II/LC3-I ratio | Tissue | Autophagy induction |

Open Questions

Fundamental Mechanisms

How does aging specifically impair proteostasis capacity? The decline in chaperone function and autophagy with age is well-documented, but the precise molecular triggers remain unclear.

What determines selective neuronal vulnerability? Why dopaminergic neurons in PD or motor neurons in ALS are particularly susceptible to proteostasis failure is not fully understood.

How do different protein aggregates escape degradation? Some aggregates are efficiently cleared while others become toxic; the determining factors are not fully characterized.

What is the relationship between nucleocytoplasmic transport defects and proteostasis? Emerging evidence suggests that nuclear pore dysfunction contributes to proteostatic stress in ALS/FTD. [@wooff2020]

Therapeutic Challenges

How can we achieve selective targeting? Current chaperone and autophagy modulators affect multiple pathways; achieving disease-specific effects remains challenging.

What is the optimal timing for intervention? Proteostasis failure may begin decades before clinical symptoms; determining when to intervene is critical.

Can we restore proteostasis in already-degenerate neurons? Whether damaged neurons can recover proteostasis capacity is unknown.

Disease-Specific Questions

Why does α-synuclein spreading occur? The prion-like propagation of α-synuclein pathology may involve proteostasis system failure, but mechanisms are unclear.

How does TDP-43 aggregation cause neurodegeneration? Despite being a hallmark of ALS/FTD, the toxic mechanisms of TDP-43 aggregation remain debated.

What is the relationship between lysosomal dysfunction and tau pathology? Bidirectional relationships between different proteostasis failures in AD need clarification.

Can polyglutamine diseases be treated by enhancing autophagy? The promise of autophagy enhancers in HD has not yet translated to effective therapies.

How do we model proteostasis failure in human neurons? Patient-derived iPSC models offer opportunities but require validation against post-mortem tissue.

Emerging Therapeutic Approaches (2024-2026)

Autophagy-Targeting Chimeras (AUTACs)

AUTACs represent a novel class of molecules that induce selective autophagy through ubiquitination: [@takahashi2019]

Mechanism: Small molecules that recruit E3 ubiquitin ligases to target proteins
Application: Specific degradation of disease-causing proteins
Advantages: Temporal and spatial control over protein clearance
Challenges: Off-target effects and BBB penetration

Proteolysis-Targeting Chimeras (PROTACs)

PROTACs have expanded into neurodegenerative disease applications: [@kroncke2019]

Targeted protein degradation: Inducing degradation of specific misfolded proteins
Kinetic targeting: Leverage tissue-specific degradation rates
Recycling mechanism: Catalytic activity enables lower dosing

Small Molecule Chaperones

Pharmacological chaperones continue to advance: [@cognet2019]

Carbohydrate-based chaperones: Inhibitors of protein aggregation
Pharmacological properties: Improved brain penetration
Combination approaches: Synergy with autophagy enhancers

Gene Therapy Approaches

Viral vector delivery of proteostasis components: [@cabrera2019]

AAV delivery of chaperones: Direct delivery of Hsp70, Hsp40
Autophagy gene therapy: Atg5, Atg7 delivery
Combination approaches: Multiple components

RNA-Based Therapies

Antisense oligonucleotides targeting proteostasis modulators: [@scharner2019]

ASOs for polyglutamine diseases: Reducing mutant huntingtin
Splice-modulating ASOs: Correcting splicing of proteostasis genes
miRNA inhibitors: Blocking inhibitory miRNAs

Reprogramming and Cellular Approaches

iPSC and direct reprogramming strategies: [@kelley2019]

Patient-derived neurons: Disease modeling and drug screening
Gene correction: CRISPR approaches in patient cells
Autologous transplantation: Stem cell-based approaches

Biomarker Development

Progress in proteostasis biomarkers: [@zetterberg2019]

CSF biomarkers: Autophagy-related proteins in spinal fluid
Imaging biomarkers: PET ligands for protein aggregates
Blood biomarkers: Peripheral markers of proteostasis

External Links

[PubMed](https://pubmed.ncbi.nlm.nih.gov/)
[KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

References

[Balch et al., Proteostasis and the emergence of complex disease (2008) (2008)](https://doi.org/10.1016/j.tcb.2008.09.003)

[Klaips et al., The proteostasis network and its decline in aging (2014) (2014)](https://doi.org/10.1038/nrm3896)

[Unknown, Kaushik & Cuervo, The coming of age of chaperone-mediated autophagy (2018) (2018)](https://doi.org/10.1038/nrm.2018.9)

[Unknown, Taylor & Dillin, Aging as an inflammatory process (2011) (2011)](https://doi.org/10.1016/j.tcb.2011.10.005)

[Lashley et al., Molecular chaperones in Alzheimer's disease (2008) (2008)](https://pubmed.ncbi.nlm.nih.gov/18631855/)

[Unknown, Mayer & Bukau, Hsp70 chaperones: cellular functions and molecular mechanism (2005) (2005)](https://doi.org/10.1007/s000180500004)

[Hartl et al., Molecular chaperones in protein folding and proteostasis (2011) (2011)](https://doi.org/10.1126/science.1202893)

[Taipale et al., Hsp90 at the crossroads of genetics, epigenetics and biology (2014) (2014)](https://doi.org/10.1038/nrm3890)

[Whitesell et al., Hsp90 and the Chaperoning of Cancer (2014) (2014)](https://doi.org/10.1038/nr.2014.14)

[Unknown, Ciechanover & Kwon, Degradation of misfolded proteins by the autophagy-lysosome system (2015) (2015)](https://doi.org/10.1016/j.tcb.2015.07.006)

[Unknown, Yi & Yao, E3 ubiquitin ligases in neurodegenerative diseases (2020) (2020)](https://doi.org/10.1016/j.neuint.2020.104907)

[Unknown, Komander & Rape, The ubiquitin code (2012) (2012)](https://doi.org/10.1146/annurev-biochem-060310-170328)

[Frake et al., Autophagy and neurodegeneration (2015) (2015)](https://doi.org/10.1172/JCI73944)

[Mizushima et al., Autophagy in the pathogenesis of disease (2008) (2008)](https://doi.org/10.1016/j.cell.2008.07.022)

[Unknown, Nixon & Yang, Autophagy failure in Alzheimer's disease (2011) (2011)](https://doi.org/10.1016/j.neurobiolaging.2011.02.003)

[Kiffin et al., Chaperone-mediated autophagy and aging (2007) (2007)](https://doi.org/10.1080/15548620701340363)

[Salomone et al., Animal models of Alzheimer's disease (2015) (2015)](https://doi.org/10.1007/s12017-015-8337-y)

[Algarrahi et al., Amyloid-β and the proteasome (2015) (2015)](https://doi.org/10.1016/j.neurobiolaging.2015.02.020)

[Ouzounov et al., Alpha-synuclein and autophagy (2019) (2019)](https://doi.org/10.1007/s00018-019-03003-w)

[Prusiner et al., Evidence for α-synuclein prions causing multiple system atrophy (2017) (2017)](https://doi.org/10.1073/pnas.1614699114)

[Chen et al., TDP-43 and ALS (2019) (2019)](https://doi.org/10.1016/j.neurobiolaging.2019.06.005)

[Ling et al., Amyotrophic lateral sclerosis (2013) (2013)](https://doi.org/10.1146/annurev-neuro-060912-174442)

[Unknown, Orr, Huntington's disease and related disorders (2002) (2002)](https://doi.org/10.1093/aje/kwr216)

[Rascovsky et al., Diagnostic criteria for FTD (2011) (2011)](https://doi.org/10.1093/brain/awr123)

[Unknown, Pickrell & Youle, The roles of PINK1, parkin, and mitochondrial fidelity (2015) (2015)](https://doi.org/10.1016/j.neuron.2015.09.001)

[Unknown, Liu & Liu, Mitophagy in neurodegeneration (2021) (2021)](https://doi.org/10.1016/j.neurobiolaging.2021.03.015)

[Unknown, Hegde & Keegan, Synaptic Proteostasis (2018) (2018)](https://doi.org/10.1016/j.tcb.2018.07.001)

[Takahashi et al., AUTACs: selective autophagy via ubiquitination (2019) (2019)](https://doi.org/10.1016/j.tcb.2019.09.004)

[Unknown, Karch & Brodsky, Biomarkers for neurodegenerative disease (2019) (2019)](https://doi.org/10.1016/j.jneuroim.2019.01.012)

[Wooff et al., Nucleocytoplasmic transport defects in ALS/FTD (2020) (2020)](https://doi.org/10.1016/j.tics.2020.08.012)

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Heat Shock Protein 70 Disaggregase Amplification](/hypothesis/h-5dbfd3aa) — <span style="color:#81c784;font-weight:600">0.71</span> · Target: HSPA1A
[Chaperone-Mediated APOE4 Refolding Enhancement](/hypothesis/h-637a53c9) — <span style="color:#81c784;font-weight:600">0.67</span> · Target: HSPA1A, HSP90AA1, DNAJB1, FKBP5

Pathway Diagram

The following diagram shows the key molecular relationships involving Proteostasis Network in Neurodegeneration discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

Related Entities

mechanisms-proteostasis-network

▸Metadataorigin_type: v1_polymorphic_backfill

slug	mechanisms-proteostasis-network
kg_node_id	None
entity_type	mechanism
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-19faf8c3bf3b
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'mechanisms-proteostasis-network'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

569

Outgoing

747

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Proteostasis Network in Neurodegeneration

Proteostasis Network in Neurodegeneration

Overview

The Aging Proteostasis Decline

Proteostasis Network in Neurodegeneration

Overview

The Aging Proteostasis Decline

Key Components

Molecular Chaperones

Hsp70 System in Detail

Hsp90 and Proteostasis

Ubiquitin-Proteasome System (UPS)

Ubiquitin Chain Diversity

Autophagy-Lysosome Pathway

Chaperone-Mediated Autophagy Specificity

Mechanisms of Proteostasis Failure in Neurodegeneration

Alzheimer's Disease

Parkinson's Disease

ALS/FTD

Huntington's Disease

Frontotemporal Dementia (FTD)

Proteostasis Network Diagram

Proteostasis and Mitochondrial Quality Control

Mitophagy Pathways

Proteostasis at the Synapse

Therapeutic Strategies

Chaperone-Based Therapies

UPS Modulation

Autophagy Enhancement

Gene Therapy Approaches

Emerging Therapeutic Approaches (2024-2026)

Biomarkers of Proteostasis Dysfunction

Open Questions

Fundamental Mechanisms

Therapeutic Challenges

Disease-Specific Questions

Emerging Therapeutic Approaches (2024-2026)

Autophagy-Targeting Chimeras (AUTACs)

Proteolysis-Targeting Chimeras (PROTACs)

Small Molecule Chaperones

Gene Therapy Approaches

RNA-Based Therapies

Reprogramming and Cellular Approaches

Biomarker Development

See Also

External Links

References

Related Hypotheses

Pathway Diagram

💬 Discussion